ii
iii
recent
avail
effect
vaccin
hepat
b
viru
hbv
estim
protect
efficaci
cost
approxim
threedos
seri
rais
question
practic
dermatologist
dermatologist
signific
risk
hbv
immun
determin
vaccin
safe
way
prevent
diseas
vaccin
fifteen
thirti
percent
health
care
worker
frequent
blood
contact
serolog
marker
hbv
infect
tabl
rhosi
die
hbvrelat
liver
cancer
major
hbv
serolog
test
avail
commerci
state
health
depart
center
diseas
control
hepat
b
surfac
antigen
hbsag
hepat
b
e
antigen
hbeag
hepat
b
core
antibodi
antihbc
hbsag
antibodi
antihb
hbeag
antibodi
antihb
tabl
ii
marker
hbv
preclin
acut
chronic
stage
immun
new
vaccin
question
aris
concern
safeti
popul
sourc
hbsagposit
plasma
start
materi
vaccin
increas
risk
acquir
immun
defici
syndrom
aid
group
clinic
entiti
associ
specif
immun
defici
manifest
kaposi
sarcoma
variou
opportunist
infect
recogn
sinc
donor
group
screen
complet
physic
examin
histori
laboratori
test
includ
hemoglobin
hematocrit
serum
protein
must
normal
although
serum
aminotransferas
may
elev
must
stabl
process
use
prepar
vaccin
design
remov
inactiv
virus
use
biophys
ammonium
sulfat
precipit
isopykn
band
zonal
separ
denatur
procedur
pepsin
ph
urea
formalin
virus
known
elimin
inactiv
process
includ
hbv
rhabdoviru
poxviru
togaviru
reoviru
herpesviru
coronaviru
myxoviru
picornaviru
kuru
creutzfeldtjakob
parvoviru
retroviru
delta
agent
nona
nonb
hepat
viru
test
safeti
use
includ
anim
cell
cultur
inocul
technic
fall
person
receiv
vaccin
observ
period
year
side
effect
primarili
relat
sore
inject
site
formaldehyd
alum
hepat
b
viru
vaccin
safeti
report
interageney
group
morbid
mortal
weekli
rep
thimeros
use
process
approxim
lowgrad
fever
vaccin
neither
therapeut
advers
effect
hbv
carrier
immun
individu
advers
effect
vaccin
therefor
essenti
screen
vaccin
presenc
antigen
antibodi
three
intramuscular
inject
ml
g
recommend
second
third
dose
month
first
durat
protect
need
booster
dose
determin
antibodi
provid
protect
persist
least
year
receiv
three
dose
probabl
last
year
booster
may
necessaryt
intermediaterisk
group
dermatologist
appropri
hbv
serolog
test
would
seem
desir
approxim
cost
test
antigen
antibodi
wear
glove
hbsag
carrier
nonimmun
physician
expos
blood
type
surgic
procedur
seem
mandatori
sinc
prevent
transmiss
hbv
doctor
patient
glove
surgic
procedur
also
seem
prudent
protect
nona
nonb
hepat
test
patient
hbsag
prior
surgeri
serv
forewarn
surgeon
potenti
danger
vaccin
allevi
consider
gamma
globulin
prophylaxi
nonimmun
physician
accident
glove
punctur
nonimmun
der
journal
american
academi
dermatolog
matologist
care
consid
hbv
immun
appear
safe
effect
without
deleteri
longterm
side
effect
dermatologist
assist
perform
surgeri
associ
aerosol
dispers
dermabras
immun
hbsagand
antihbsneg
meanwhil
molecular
engin
insert
hbsag
gene
microorgan
may
result
even
safer
less
expens
vaccin
